RISEDRONATE SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Risedronate Sodium patents expire, and what generic alternatives are available?
Risedronate Sodium is a drug marketed by Impax Labs Inc, Sun Pharm, Teva Pharms Usa, Zydus Pharms, Apotex, Aurobindo Pharma, Aurobindo Pharma Ltd, Hangzhou Binjiang, Macleods Pharms Ltd, Norvium Bioscience, and Orbion Pharms. and is included in fourteen NDAs.
The generic ingredient in RISEDRONATE SODIUM is risedronate sodium. There are nineteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the risedronate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Risedronate Sodium
A generic version of RISEDRONATE SODIUM was approved as risedronate sodium by TEVA PHARMS USA on October 5th, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RISEDRONATE SODIUM?
- What are the global sales for RISEDRONATE SODIUM?
- What is Average Wholesale Price for RISEDRONATE SODIUM?
Summary for RISEDRONATE SODIUM
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 14 |
| Finished Product Suppliers / Packagers: | 11 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 16 |
| Patent Applications: | 2,193 |
| Drug Prices: | Drug price information for RISEDRONATE SODIUM |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RISEDRONATE SODIUM |
| What excipients (inactive ingredients) are in RISEDRONATE SODIUM? | RISEDRONATE SODIUM excipients list |
| DailyMed Link: | RISEDRONATE SODIUM at DailyMed |
Recent Clinical Trials for RISEDRONATE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sheffield Children's NHS Foundation Trust | Phase 2 |
| Takeda | |
| Chugai Pharmaceutical | Phase 3 |
Pharmacology for RISEDRONATE SODIUM
| Drug Class | Bisphosphonate |
Medical Subject Heading (MeSH) Categories for RISEDRONATE SODIUM
Paragraph IV (Patent) Challenges for RISEDRONATE SODIUM
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ATELVIA | Delayed-release Tablets | risedronate sodium | 35 mg | 022560 | 1 | 2011-06-09 |
| ACTONEL | Tablets | risedronate sodium | 150 mg | 020835 | 1 | 2008-08-12 |
| ACTONEL | Tablets | risedronate sodium | 75 mg | 020835 | 1 | 2007-09-07 |
| ACTONEL | Tablets | risedronate sodium | 5 mg, 30 mg and 35 mg | 020835 | 1 | 2004-04-23 |
US Patents and Regulatory Information for RISEDRONATE SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | RISEDRONATE SODIUM | risedronate sodium | TABLET;ORAL | 077132-001 | Oct 5, 2007 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa | RISEDRONATE SODIUM | risedronate sodium | TABLET;ORAL | 077132-002 | Oct 5, 2007 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Impax Labs Inc | RISEDRONATE SODIUM | risedronate sodium | TABLET, DELAYED RELEASE;ORAL | 205066-001 | Jun 29, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
